MA33488B1 - Motifs de modification chimique pour des inhibiteurs et mimétiques de miarn - Google Patents

Motifs de modification chimique pour des inhibiteurs et mimétiques de miarn

Info

Publication number
MA33488B1
MA33488B1 MA34505A MA34505A MA33488B1 MA 33488 B1 MA33488 B1 MA 33488B1 MA 34505 A MA34505 A MA 34505A MA 34505 A MA34505 A MA 34505A MA 33488 B1 MA33488 B1 MA 33488B1
Authority
MA
Morocco
Prior art keywords
mimetics
inhibitors
mirik
chemical modification
modification rules
Prior art date
Application number
MA34505A
Other languages
English (en)
Inventor
Christina Yamada
William S Marshall
Original Assignee
Miragen Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Miragen Therapeutics filed Critical Miragen Therapeutics
Publication of MA33488B1 publication Critical patent/MA33488B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/332—Abasic residue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des polynucléotides ayant des motifs de chimie qui confèrent une stabilité, activité et/ou toxicité améliorée(s) par rapport à leur utilisation en tant qu'inhibiteurs de miARN ou mimétiques de miARN. L'invention concerne en outre des compositions pharmaceutiques et formulations comprenant les polynucléotides, et des procédés pour traiter des patients ayant une affection associée à l'expression de miARN ou d'ARNm.
MA34505A 2009-06-08 2010-06-08 Motifs de modification chimique pour des inhibiteurs et mimétiques de miarn MA33488B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18503309P 2009-06-08 2009-06-08
PCT/US2010/037821 WO2010144485A1 (fr) 2009-06-08 2010-06-08 Motifs de modification chimique pour des inhibiteurs et mimétiques de miarn

Publications (1)

Publication Number Publication Date
MA33488B1 true MA33488B1 (fr) 2012-08-01

Family

ID=43309198

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34505A MA33488B1 (fr) 2009-06-08 2010-06-08 Motifs de modification chimique pour des inhibiteurs et mimétiques de miarn

Country Status (17)

Country Link
US (2) US20120148664A1 (fr)
EP (1) EP2440566A4 (fr)
JP (1) JP2012529295A (fr)
KR (1) KR20120047892A (fr)
CN (1) CN102803284B (fr)
AU (1) AU2010258875A1 (fr)
BR (1) BRPI1010885A2 (fr)
CA (1) CA2765129A1 (fr)
EA (1) EA022757B1 (fr)
GE (1) GEP20156329B (fr)
MA (1) MA33488B1 (fr)
MX (1) MX2011013176A (fr)
NZ (1) NZ597078A (fr)
SG (1) SG176716A1 (fr)
UA (1) UA105390C2 (fr)
WO (1) WO2010144485A1 (fr)
ZA (1) ZA201109319B (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6047270B2 (ja) 2006-08-11 2016-12-21 バイオマリン テクノロジーズ ベー．フェー． Ｄｎａリピートの不安定性に関連した遺伝的障害を治療するための方法及び手段
EP2203173B1 (fr) 2007-10-26 2015-12-23 Academisch Ziekenhuis Leiden Moyens et procédé de compensation des troubles musculaires
CA2789404C (fr) 2010-02-26 2020-03-24 Columbia University Procedes et compositions destines a la detection et au traitement du cancer impliquant des miarn et des inhibiteurs des miarn ainsi que des cibles
US20120116381A1 (en) 2010-11-05 2012-05-10 Houser Kevin L Surgical instrument with charging station and wireless communication
AR084319A1 (es) 2010-12-15 2013-05-08 Miragen Therapeutics INHIBIDORES DE microARN (miARN O miR) QUE COMPRENDEN NUCLEOTIDOS BLOQUEADOS
CN102643807B (zh) * 2011-02-18 2015-06-03 中国科学院上海药物研究所 人miR-484的反义寡聚核苷酸及其应用
CA2833223A1 (fr) * 2011-04-22 2012-10-26 Prosensa Technologies B.V. Nouveaux composes pour traiter, retarder et/ou prevenir un trouble genetique humain, tel que la dystrophie myotonique de type 1 (dm1)
WO2012148952A1 (fr) * 2011-04-25 2012-11-01 Regulus Therapeutics Inc Composés microarn et procédés pour la modulation de l'activité de mir-21
WO2012149646A1 (fr) * 2011-05-05 2012-11-08 Sunnybrook Research Institute Inhibiteurs d'arnmi et leurs utilisations
WO2012153135A1 (fr) * 2011-05-09 2012-11-15 University Of Glasgow Procédés de modulation de microarn dans le traitement de l'hypertension artérielle pulmonaire
CA2850223A1 (fr) 2011-10-06 2013-04-11 Eva Van Rooij Regulation de l'homeostasie energetique du corps entier par la regulation de microarn
CN118581086A (zh) 2012-01-27 2024-09-03 比奥马林技术公司 用于治疗杜兴型肌营养不良症和贝克型肌营养不良症的具有改善特性的rna调节性寡核苷酸
EP3604536B1 (fr) 2012-04-23 2024-05-29 Vico Therapeutics B.V. Oligonucléotides de modulation arn présentant des caractéristiques améliorées pour le traitement des troubles neuromusculaires
EP2841579B1 (fr) * 2012-04-25 2018-10-10 Regulus Therapeutics Inc. Composés microarn et méthodes pour la modulation de l'activité du mir-21
CN102703456B (zh) * 2012-05-15 2014-04-02 武汉生命之美科技有限公司 DAPK3基因hsa-miR-20a的作用靶位点
US9163235B2 (en) 2012-06-21 2015-10-20 MiRagen Therapeutics, Inc. Inhibitors of the miR-15 family of micro-RNAs
CN104685056A (zh) 2012-06-21 2015-06-03 米拉根医疗股份有限公司 包含锁核酸基序的基于寡核苷酸的抑制剂
UA116639C2 (uk) 2012-10-09 2018-04-25 Рег'Юлес Терап'Ютікс Інк. Способи лікування синдрому альпорта
CN105188715B (zh) * 2013-03-15 2018-12-25 米拉根医疗股份有限公司 Mir-145的锁定核酸抑制剂及其用途
EP2992095B1 (fr) 2013-05-01 2019-01-09 Regulus Therapeutics Inc. Composés microarn et procédés permettant la modulation de l'activité de mir-122
CN103290011B (zh) * 2013-05-16 2015-09-16 南京市妇幼保健院 与胎儿先天性心脏病相关的母体血清/血浆miRNA标志物mir-29c及其应用
CN103667441B (zh) * 2013-09-10 2016-10-19 山西医科大学第一医院 一种Hsa-miR-145-5p试剂盒及其成熟体模拟物的应用
GB201400598D0 (en) 2014-01-14 2014-03-05 Univ Glasgow Materials and methods for modulation of tendon healing
CN104083761A (zh) * 2014-06-25 2014-10-08 北京大学第三医院 microRNA-101抑制剂在制备预防或治疗骨关节炎药物中的应用
US9487783B2 (en) 2014-08-07 2016-11-08 Regulus Therapeutics Inc. Targeting microRNAs for metabolic disorders
CN107636003A (zh) 2015-01-20 2018-01-26 米拉根医疗股份有限公司 miR‑92抑制剂及其用途
CN108368507B (zh) * 2015-09-02 2022-03-22 阿尔尼拉姆医药品有限公司 程序性细胞死亡1配体1(PD-L1)的iRNA组合物及其使用方法
WO2017043490A1 (fr) * 2015-09-07 2017-03-16 協和発酵バイオ株式会社 Acide ribonucléique double brin possédant un effet amélioré d'induction de l'immunité naturelle
DK3426781T3 (da) * 2016-03-07 2024-09-30 Us Health Mikro-rna'er og fremgangsmåder til anvendelse deraf
US20190127736A1 (en) 2016-04-29 2019-05-02 Aptamir Therapeutics, Inc. Inhibition of mir-22 mirna by apt-110
CN110088278B (zh) * 2016-10-31 2023-08-11 e-NA生物科技公司 双链核酸分子及其用途
AU2017368050A1 (en) 2016-11-29 2019-06-20 Puretech Lyt, Inc. Exosomes for delivery of therapeutic agents
US11753639B2 (en) 2018-03-14 2023-09-12 Beth Israel Deaconess Medical Center Micro-RNA and obesity
EP3790972A1 (fr) 2018-05-08 2021-03-17 Regulus Therapeutics Inc. Oligonucléotide modifié conjugué à galnac en tant qu'inhibiteur de mir-122 ayant une activité antivirale contre le vhc à effet secondaire d'hyperbilirubinémie réduit
US11015197B2 (en) 2018-08-29 2021-05-25 Korea Institute Of Science And Technology Therapeutic agent for treating cancer comprising anti-miRNA-albumin composite
BR112022019889A2 (pt) 2020-04-02 2023-03-07 Mirecule Inc Inibição direcionada com o uso de oligonucleotídeos modificados geneticamente
CN116438305A (zh) * 2020-07-23 2023-07-14 法兰克福大学 用于治疗心力衰竭的miRNA的组合抑制
WO2023014972A2 (fr) * 2021-08-06 2023-02-09 New York R&D Center For Translational Medicine And Therapeutics, Inc. Compositions de microarn et procédés d'utilisation

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981505A (en) 1993-01-26 1999-11-09 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
US5837533A (en) 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
US5840710A (en) 1994-12-09 1998-11-24 Genzyme Corporation Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules
US5998203A (en) 1996-04-16 1999-12-07 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
US6217900B1 (en) 1997-04-30 2001-04-17 American Home Products Corporation Vesicular complexes and methods of making and using the same
DE10049549A1 (de) * 2000-10-06 2002-05-02 Markus Hecker Modulation der Transkription pro-inflammatorischer Genprodukte
EP2530157B1 (fr) * 2003-07-31 2016-09-28 Regulus Therapeutics Inc. Composés oligomères et compositions à utiliser dans la modulation de miARNs
JP5192234B2 (ja) * 2004-08-10 2013-05-08 アルナイラム ファーマシューティカルズ， インコーポレイテッド 化学修飾オリゴヌクレオチド
CN101426912A (zh) * 2005-08-17 2009-05-06 瑟纳治疗公司 介导rna干扰的化学修饰短干扰核酸分子
US20080287383A1 (en) * 2007-03-02 2008-11-20 Nastech Pharmaceutical Company Inc. Nucleic acid compounds for inhibiting erbb gene expression and uses thereof
ES2463665T3 (es) 2007-10-04 2014-05-28 Stella Aps Tratamiento de combinación para el tratamiento de infección por virus de la hepatitis C
MX2010005166A (es) * 2007-11-09 2010-10-07 Univ Texas Micro arn de la familia mir-15 que modulan la sobrevivencia de cardiomiocitos y reparacion cardiaca.

Also Published As

Publication number Publication date
CN102803284A (zh) 2012-11-28
EP2440566A1 (fr) 2012-04-18
US20120148664A1 (en) 2012-06-14
UA105390C2 (ru) 2014-05-12
JP2012529295A (ja) 2012-11-22
WO2010144485A1 (fr) 2010-12-16
MX2011013176A (es) 2012-04-30
EP2440566A4 (fr) 2013-10-16
KR20120047892A (ko) 2012-05-14
BRPI1010885A2 (pt) 2015-09-22
SG176716A1 (en) 2012-01-30
EA201171493A1 (ru) 2012-06-29
US20140066491A1 (en) 2014-03-06
EA022757B1 (ru) 2016-02-29
NZ597078A (en) 2013-11-29
CA2765129A1 (fr) 2010-12-16
GEP20156329B (en) 2015-07-27
CN102803284B (zh) 2015-11-25
AU2010258875A1 (en) 2012-01-19
ZA201109319B (en) 2013-02-27

Similar Documents

Publication Publication Date Title
UA105390C2 (ru) МОТИВЫ ХИМИЧЕСКИХ МОДИФИКАЦИЙ ДЛЯ ИНГИБИТОРОВ И МИМЕТИКОВ мкРНК
MD20150043A2 (ro) Inhibitori ai histon-demetilazelor
EP2493464A4 (fr) Méthylsulfonylméthane (msm) pour le traitement de micro-organismes résistants aux médicaments
PH12013501955A1 (en) Viral inhibitor composition for in vivo therapeutic use
EA201070421A1 (ru) Микрорибонуклеиновые кислоты
PH12013502090A1 (en) 1,3 oxazines as bace1 and/or bace2 inhibitors
PH12013502316A1 (en) Halogen-alkyl-1,3 oxazines as bace1 and/or bace2 inhibitors
UA108369C2 (uk) Піролопіримідини як інгібітори cdk4/6
PH12013502262A1 (en) Spiro-[1,3]-oxazines and spiro-[1,4]-oxazepines as bace1 and/or bace2 inhibitors
SG179120A1 (en) Novel compounds
BR112013008140A2 (pt) "compostos imidazotriazinona".
MX336381B (es) Boronatos como inhibidores de arginasa.
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
EA201270666A1 (ru) Соединения и фармацевтические композиции для снижения уровня мочевой кислоты
MX2013007558A (es) 1,4-oxazinas como inhibidores de los genes enzima de segmentacion de la proteina precursora del sitio 1 y/o 2 (bace1 y/o bace2).
MX2009007345A (es) Compuestos con (fenil sustituido), con restos de propenal, sus derivados, actividad biologica y uso del mismo.
MX2013007957A (es) 1,4-oxazinas como inhibidores de los genes de enzima de segmentacion de la proteina precursora amiloide del sitio beta 1 y/o (bace1 y/o bace2).
UA113538C2 (xx) Фторметил-5,6-дигідро-4h-$1,3]оксазини
CR20130264A (es) Compuestos pirimidinona para uso en el tratamiento de enfermedades o condiciones mediadas por lp-pla2
SG195100A1 (en) Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors
WO2009036341A3 (fr) Compositions et procédés liés à l'inhibition de la vih protéase
PH12014502541A1 (en) 5-amino [1,4] thiazines as bace 1 inhibitors
MA32061B1 (fr) Triazolopyridazines en tant qu'inhibiteurs de par1, production de celles-ci, et utilisation en tant que médicaments
PT1981862E (pt) Compostos relacionados com lantionina para o tratamento de doenças inflamatórias
MX2010000956A (es) Derivados de isoftalamida que inhiben actividad de beta-secretasa.